DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Journal of Antimicrobial Chemotherapy Année : 2024

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine

Justine Sourice
  • Fonction : Auteur
Véronique Avettand-Fenoel
Stéphanie Marque Juillet
  • Fonction : Auteur
Brigitte Montes
  • Fonction : Auteur

Résumé

Abstract Background Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF. Methods A retrospective national survey of PLWHIV who were either naive or experienced on antiretroviral treatment including doravirine was conducted. VF was defined as two consecutive plasma viral loads (VLs) of ≥50 copies/mL or one VL of ≥200 copies/mL. Genotypic resistance tests were interpreted using the Stanford (v9.4.1) and ANRS (v33) algorithms. Results Of the 589 PLWHIV treated with a doravirine-containing regimen, 8.5% were naive and 91.5% had prior antiretroviral experience; 56.9% were infected with HIV-1 B subtype. Overall, 88.3% and 85.1% of participants were virologically controlled at Month (M)3 and M6 of doravirine treatment, respectively. In multivariable analysis, CRF02_AG subtype, higher zenith plasma HIV-1 RNA VL, doravirine initiation in the context of failure and baseline V179D mutation presence were associated with VF. Among 88 PLWHIV who experienced virological failure at M6, 15.9% had a median of 2 (IQR 1–3) HIV RT mutations. In multivariable analysis, the only factor associated with the occurrence of mutations was a genotypic sensitivity score that was not fully sensitive. Conclusions This study is one of the largest to characterize the virological efficacy of doravirine-containing regimens in clinical practice and to identify factors associated with VF or emergence of resistance mutations that should be considered in clinical management.
Fichier non déposé

Dates et versions

hal-04619199 , version 1 (20-06-2024)

Identifiants

Citer

Cathia Soulie, Aliou Balde, Djeneba Fofana, Charlotte Charpentier, Pascale Bonnafous, et al.. DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine. Journal of Antimicrobial Chemotherapy, 2024, ⟨10.1093/jac/dkae194⟩. ⟨hal-04619199⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More